Edwards Lifesciences (EW) Q3 EPS $0.531 vs $0.76 est.
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, up 10.5% year over year and 11.2% on a constant-currency basis, while adjusted EPS of $0.801 grew 19% and topped the $0.76 consensus estimate; GAAP EPS of $0.531 missed that mark. TAVR sales rose 8.0% to $1.24 billion, or 8.8% in constant currency, and TMTT sales jumped 44.0% to $207 million, or 45.6% in constant currency. The company also raised its full-year 2026 outlook, though the release did not specify the new figures. The quarter's growth was driven by the transcatheter heart valve franchise and the faster-growing TMTT segment, with the adjusted beat offsetting the GAAP miss. Investors will watch the updated 2026 guidance details and whether TAVR growth can accelerate from its high-single-digit pace.
Muhabbit's AI wrote this summary in its own words from Business Wire's report. It can get details wrong, so check the source.
Named in this story
Edwards Lifesciences (EW), NYSE: EW
A linked name opens that asset's sentiment page.